Aspira Women’s Health Selected as a Spoke for the Investor Catalyst Hub
05 9월 2024 - 9:00PM
Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a
bio-analytical based women’s health company focused on the
development of gynecologic disease diagnostic tools, today
announced that it was selected as a spoke for the Investor Catalyst
Hub, a regional hub of ARPANET-H, a nationwide health innovation
network launched by the Advanced Research Projects Agency for
Health (ARPA-H). Based in the Greater Boston area and managed by
VentureWell, the Investor Catalyst Hub seeks to accelerate the
commercialization of groundbreaking and accessible biomedical
solutions. It utilizes an innovative hub-and-spoke model designed
to reach a wide range of nonprofit organizations and
Minority-Serving Institutions, with the ultimate aim of delivering
scalable healthcare outcomes for all Americans.
“It is an honor to join the Investor Catalyst Hub alongside so
many of healthcare’s most impactful organizations. Our mission to
radically improve gynecologic health outcomes through the
development of AI-powered diagnostic solutions is perfectly aligned
with the objectives of the Hub, and we look forward to playing a
leadership role in the acceleration of progress across the entire
ecosystem,” stated Nicole Sandford, Aspira’s CEO.
Aspira joins a dynamic nationwide network of organizations
aligned to ARPA-H’s overarching mission to improve health outcomes
through the following research focus areas: health science futures,
proactive health, scalable solutions, and resilient systems.
Investor Catalyst Hub spokes represent a broad spectrum of
expertise, geographic diversity, and community perspectives.
“Our spoke network embodies a rich and representative range of
perspectives and expertise,” said Mark Marino, Vice President of
Growth Strategy and Development for VentureWell and Project
Director for the Investor Catalyst Hub. “Our spokes comprise a
diverse network that will be instrumental in ensuring that
equitable health solutions reach communities across every state and
tribal nation.”
As an Investor Catalyst Hub spoke, Aspira gains access to
potential funding and flexible contracting for faster award
execution compared to traditional government contracts. Spoke
membership also offers opportunities to provide input on ARPA-H
challenge areas and priorities, along with access to valuable
networking opportunities and a robust resource library. The spoke
network will continue to grow as the Investor Catalyst Hub expands
its efforts, with applications being selected on a rolling basis.
Interested organizations can visit https://investorcatalysthub.org/
to learn more or submit a membership application.
About Aspira Women’s Health Inc.Aspira Women’s
Health Inc. is dedicated to the discovery, development, and
commercialization of noninvasive, AI-powered tests to aid in the
diagnosis of gynecologic diseases.
OvaWatch® and Ova1Plus® are offered to clinicians as OvaSuiteSM.
Together, they provide the only comprehensive portfolio of blood
tests to aid in the detection of ovarian cancer for the 1.2+
million American women diagnosed with an adnexal mass each year.
OvaWatch provides a negative predictive value of 99% and is used to
assess ovarian cancer risk for women where initial clinical
assessment indicates the mass is indeterminate or benign, and thus
surgery may be premature or unnecessary. Ova1Plus is a reflex
process of two FDA-cleared tests, Ova1® and Overa®, to assess the
risk of ovarian malignancy in women planned for
surgery.
Our in-development test pipeline is designed to expand our
ovarian cancer portfolio and addresses the tremendous need for
noninvasive diagnostics for endometriosis, a debilitating disease
that impacts millions of women worldwide. In ovarian cancer, our
OvaMDx risk assessment is designed to combine microRNA and protein
biomarkers with patient data to further enhance the sensitivity and
specificity of our current tests. In endometriosis, EndoCheckSM is
the first-ever noninvasive test designed to identify endometriomas,
one of the most commonly occurring forms of endometriosis. Aspira’s
other in-development endometriosis test is designed to combine
microRNA and protein biomarkers with patient data to identify all
endometriosis.
Forward-Looking StatementsThis press release
contains forward-looking statements, as defined in the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements involve a number of risks and uncertainties. Such
forward-looking statements include statements regarding, among
other things, the timing and completion of any products in the
pipeline development and other statements that are predictive in
nature. Actual results could differ materially from those discussed
due to known and unknown risks, uncertainties, and other factors.
These forward-looking statements generally can be identified by the
use of words such as “designed to,” “expect,” “plan,” “anticipate,”
“could,” “may,” “intend,” “will,” “continue,” “future,” other words
of similar meaning and the use of future dates. Forward-looking
statements in this press release and other factors that may cause
such differences include the satisfaction of customary closing
conditions related to the offering and the expected timing of the
closing of the offering. These and additional risks and
uncertainties are described more fully in the company’s filings
with the SEC, including those factors identified as “Risk Factors”
in our most recent Annual Report on Form 10-K, for the fiscal year
ended December 31, 2023, and subsequent Quarterly Reports on Form
10-Q. If any of these risks materialize or our assumptions prove
incorrect, actual results could differ materially from the results
implied by these forward-looking statements. There may be
additional risks that Aspira presently does not know, or that
Aspira currently believes are immaterial, that could also cause
actual results to differ from those contained in the
forward-looking statements. In addition, forward-looking statements
reflect Aspira’s expectations, plans, or forecasts of future events
and views as of the date of this press release. Subsequent events
and developments may cause the Company’s assessments to change.
However, while Aspira may elect to update these forward-looking
statements at some point in the future, Aspira expressly disclaims
any obligation to do so, except as required by law. These
forward-looking statements should not be relied upon as
representing Aspira’s assessments of any date after the date of
this press release. Accordingly, undue reliance should not be
placed upon the forward-looking statements.
Investor Relations Contact: Monique
Kosse Investor Relations SpecialistInvestors@aspirawh.com
Aspira Womans Health (NASDAQ:AWH)
과거 데이터 주식 차트
부터 8월(8) 2024 으로 9월(9) 2024
Aspira Womans Health (NASDAQ:AWH)
과거 데이터 주식 차트
부터 9월(9) 2023 으로 9월(9) 2024